Cloning, Virals, Cell Reagents, etc.
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
100
NCT04824040
Clinical, Immunological, Morphological and Genetic Characteristics of Patients With Dysferlinopathy (LGMD R2) in the RF
Phase: N/A
Role: Collaborator
Start: Jan 15, 2020
Completion: Jul 31, 2027
Loading map...